Abstract:The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó and Drew Weissman in recognition of their contributions to mRNA technology. Before this groundbreaking discovery, mRNA was known to be unstable and can induce inflammatory reactions. Without overcoming this challenge, the progression of mRNA technology towards clinical applications would be hindered. In 2005, Katalin Karikó and Drew Weissman discovered that, unlike naturally synthesized mRNA, in vitro transcribed mRNA led to adverse inflammatory reactions through the release of pro-inflammatory cytokines after being recognized by dendritic cells (DC) as a foreign molecule and subsequent activation of toll-like receptor 3 (TLR3). With this knowledge, they further discovered that, by introducing naturally occurring modified nucleotides to substitute unmodified nucleotides during in vitro transcription, the activation of monocyte-derived dendritic cells (MDDC) induced by mRNA containing these modified nucleotides was significantly reduced and the inflammatory reactions could be nearly eliminated. This discovery has overcome the safety bottleneck of mRNA, unleashing the potential of mRNA technology. In the following years, with more technological breakthroughs in lipid nanoparticle (LNP)-based delivery method and large-scale mRNA production, the advantages of mRNA technology in terms of standardized development, safety, and effectiveness have become evident, and has begun to facilitate new technological breakthroughs in the prevention of infectious diseases and the treatment of cancer, genetic disorders, and autoimmune diseases. For infectious diseases that lack effective vaccines, the advantages of mRNA vaccines have ushered in new approaches to solving challenges such as encoding multiple proteins in a single vaccine and targeting rapidly evolving viruses. In addition to preventing infectious diseases, the characteristic of mRNA to express any protein within the body brought it a flexible “body reprogramming” capability, allowing the intervention for various internal abnormalities caused by multiple factors such as genetic disease, cancer, autoimmune diseases, and aging. Promising mRNA-based therapeutics have been developed targeting various inherited metabolic diseases as well as malignant tumors, and mRNA-based chimeric antigen receptor (CAR) T-cell therapy has displayed dramatically reduced complexity and cost. As if a key that opened a giant gateway, the technological breakthrough of Katalin Karikó and Drew Weissman has made the practical application of various mRNA technologies possible and allowed mRNA technologies to enter a new stage of development, which eventually played a crucial role in the global response to the coronavirus disease 2019 (COVID-19) pandemic. It has brought a paradigm shift in how we approach infectious diseases and shed new light on the treatment of incurable diseases. Therefore, this achievement has earned the prestigious 2023 Nobel Prize in Physiology or Medicine.This paper reviews the early research trajectory of mRNA technology and the technical challenges encountered during its transition into practical applications, interprets Katalin Karikó and Drew Weissman’s technological breakthroughs, and provides a brief analysis of the new opportunities that mRNA technology presents to the field of medicine. By exploring the “past and present” of mRNA technology, this paper aims to highlight the profound significance and transformative impact of the achievement that was awarded the 2023 Nobel Prize in Physiology or Medicine.

Tweaks in vaccine

Chronological Management of Adjuvant Effect for Optimized Mrna Vaccine Inspired by Natural Virus Infection.

The pivotal role of uridine modifications in the development of mRNA technology

Analyses of the 2023 Nobel Prize in Physiology or Medicine: Nucleoside Base Modifications and Effective mRNA Vaccines

In Vitro Transcribed mRNA Immunogenicity Induces Chemokine‐Mediated Lymphocyte Recruitment and Can Be Gradually Tailored by Uridine Modification

Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens

"Goldilocks Modifications" for mRNA Therapeutics Won the Nobel Prize

Effective Synthesis of mRNA during In Vitro Transcription with Fewer Impurities Produced

Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency

Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability

Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery

The key to practical application of mRNA technology: A brief analysis of the 2023 Nobel Prize in Physiology or Medicine

Quantitative profiling of human translation initiation reveals regulatory elements that potently affect endogenous and therapeutically modified mRNAs

Improving the fidelity of uridine analog incorporation during in vitro transcription

N 1 -methylpseudouridylation affects the fidelity of mRNA translation

Improvement of the potency of a N1-methylpseudouridine-modified self-amplifying RNA through mutations in the RNA-dependent-RNA-polymerase

Engineered mRNAs With Stable Structures Minimize Double-stranded RNA Formation and Increase Protein Expression

Strategic deactivation of mRNA COVID‐19 vaccines: New applications for siRNA therapy and RIBOTACs

Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice

A novel deep generative model for mRNA vaccine development: Designing 5ʹ UTRs with N 1-methyl-pseudouridine modification

Chemical Modifications of mRNA Ends for Therapeutic Applications